A phase I study to evaluate the dosimetry and safety of [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-DFO-AP-101, a new antibody-based radiopharmaceutical to detect misfolded SOD1 in amyotrophic lateral sclerosis. Here, SOD1 is linked to amyotrophic lateral sclerosis.